SCHEMBL20119170

SCHEMBL20119170

CN1CCc2cc(C(=O)NCC(=O)O)ccc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 2/20 0.47
ALDH1A1 P00352 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HDAC6 Q9UBN7 3/20 0.47
HDAC8 Q9BY41 2/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 1/20 0.46
WNT1 P04628 2/20 0.45
GSK3B P49841 2/20 0.45
DYRK1A Q13627 2/20 0.45
ROCK2 O75116 4/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
CYP3A4 P08684 1/20 0.45
ROCK1 Q13464 1/20 0.44
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26487314 0.84 NAMPT (0.55) OPRM1
SCHEMBL20173805 0.84 HDAC6 (0.44) USP5ALDH1A1L3MBTL1HDAC6HDAC8
SCHEMBL21882600 0.82 WNT1 (0.46) HDAC6HDAC8HTTSMN1; SMN2WNT1
SCHEMBL23077104 0.82 HDAC6 (0.52) ALDH1A1HDAC6HDAC8SMN1; SMN2KDM4E
SCHEMBL26484688 0.81 HDAC6 (0.51) HDAC6HDAC8WNT1GSK3BDYRK1A
SCHEMBL20119295 0.80 SMN1; SMN2 (0.47) HDAC6HDAC8HTTSMN1; SMN2WNT1
SCHEMBL30839551 0.80 ALDH1A1 (0.61) ALDH1A1HDAC6HDAC8
SCHEMBL3313430 0.80 ALDH1A1 (0.61) ALDH1A1HDAC6HDAC8
SCHEMBL1787470 0.79 ALDH1A1 (0.56) ALDH1A1L3MBTL1HDAC6HDAC8SMN1; SMN2
Hydrochloric Acid SCHEMBL3313566 0.79 ALDH1A1 (0.59) ALDH1A1HDAC6HDAC8WNT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
WO-2018081285-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 USP5 216/4885ALDH1A1 2185/4885L3MBTL1 4819/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 USP5 216/4885ALDH1A1 2185/4885L3MBTL1 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.